The China Securities Regulatory Commission has opened an investigation into Shenzhen Yahuilong Biotechnology Co., Ltd. over suspected misleading statements in a company announcement. The case relates to a disclosure made on 7 January 2026 concerning the signing of a strategic cooperation framework agreement. The regulator said it will handle the matter in accordance with the law following a comprehensive investigation.